Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. AUBAGIO (tériflunomide)
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

AUBAGIO (tériflunomide)

Medicine - Posted on Apr 12 2022
Active substance (DCI)
  • tériflunomide
history (4)
  • 3/30/22

    AUBAGIO (tériflunomide) - SEP récurrentes-rémittentes

    Key points Unfavourable opinion for reimbursement in the treatment of paediatric patients aged 10 years and older with relap...
    CAV :
    54321
    icône flèche
  • 10/2/19

    AUBAGIO (tériflunomide)

    L’essentiel Avis favorable au maintien du remboursement dans le traitement des patients adultes atteints de formes rémittent...
    icône flèche
  • 10/5/16

    AUBAGIO (tériflunomide)

    Maintien du remboursement dans les mêmes conditions
    icône flèche
  • 3/5/14

    AUBAGIO

    -
    CAV :
    54321
    icône flèche
Technical information
ATC code
  • L04AA31
Manufacturer
SANOFI-AVENTIS FRANCE
Presentation

AUBAGIO 14 mg, comprimé pelliculé (code CIS : 62160702)
plaquette(s) thermoformée(s) aluminium de 28 comprimé(s) - Code CIP : 34009 274 998 9 0

All our publications
    Autoimmune diseases Central nervous system diseases Demyelinating diseases Drug therapy Paediatrics

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
13yV1mhMdt9VJ3hd